Methylmalonic Acid's Surprising Impact on Cancer-Fighting T Cells

Researchers at Moffitt Cancer Center have discovered a **crucial link** between elevated levels of **methylmalonic acid** and the weakening of **CD8+ T cells**, key players in the immune response against tumors. Published in the _Oncogene_ journal, the study points to how metabolic changes tied to aging may compromise immune defenses, particularly in fighting lung cancer. High methylmalonic acid levels, often associated with aging and vitamin B12 deficiency, were found to impair the activation and effector functions of CD8+ T cells, weakening their ability to combat cancer effectively. Lead researcher **Ana Gomes, Ph.D.**, explained that methylmalonic acid disrupts energy production in CD8+ T cells, diminishing their cancer-fighting capacity. The study showed how this acid significantly reduces CD8+ T cell activity by influencing global gene expression, leading to the downregulation of crucial metabolic and immune activation pathways. The research also suggests methylmalonic acid affects the tumor microenvironment, potentially fostering conditions more conducive to tumor growth and metastasis. These findings highlight the potential of targeting methylmalonic acid as a strategy to enhance antitumor immunity, especially for older patients at higher risk of lung cancer. This groundbreaking study was supported by numerous prestigious institutions, including the National Institutes of Health and the American Cancer Society, emphasizing its importance in cancer research.